Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Camrelizumab for T4 dMMR Colon Cancer
NCT06215677Phase 2Active, not recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2024
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in colon cancer, sponsored by Peking Union Medical College Hospital. Started Jan 2024; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06215677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06215677.